Qualitative Platelet Disorders Treatment Market Trends

Growth Drivers

• Growing Changes in Lifestyle – Changes in lifestyle and nutrition among people across the globe have led to a rise in the occurrence of illnesses including obesity, diabetes, and hypertension, which are risk factors for qualitative platelet disorders. As per data, over 600,000 fatalities in the United States occur as a result of unhealthy nutrition each year.
• Rising Geriatric Population – The elderly population is more prone to qualitative platelet abnormalities and the rising number of elderly populations across the globe is estimated to drive market growth. Lately, there are more than 40 million senior citizens in the United States who are 65 or older. It is predicted that this number is expected to rise by more than 80 million by 2050.
• Increasing Health Spending – To address qualitative platelet abnormalities, surgery may occasionally be required. Increasing healthcare spending improves access to competent doctors and specialized surgical facilities wich is further expected to contribute to the market growth. According to the most recent expenditure data, health spending in the US rose by over 9% in 2020.
• Surging Demand for Drugs – It is expected that consumption of several medications, including high-dose penicillin, as well as ethanol, can cause platelet dysfunction as a side effect, which in turn is anticipated to drive the market growth. It was discovered in the US the usage of medications prescribed by retail pharmacies increased by over 2% yearly.

Challenges

• Exorbitant Cost of Treatment - The high cost associated with the treatment of qualitative platelet disorders is one of the major factors predicted to slow down the market growth. For instance, the requirement for long-term care, regular monitoring, and the use of pricey drugs or procedures, treating qualitative platelet abnormalities can be expensive. In addition, in extreme situations of qualitative platelet abnormalities, platelet transfusions can be necessary. Depending on how severe the illness is, these transfusions may need to be repeated frequently and might increase the expenses.
• Insufficient Access to Appropriate Care in Middle- and Low-Income Countries
• Absence of Reimbursement Policies